Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Vostok New Ventures Ltd in connection with its in kind acquisition of BlaBlaCar
Mandate

Vinge advises Vostok New Ventures Ltd in connection with its in kind acquisition of BlaBlaCar

November 30, 2016

The acquisition was made by an issue in kind where the purchase price for the shares in BlaBlaCar consisted of 4,154,495 newly issued shares in Vostok. A prospectus for listing of the Swedish depository receipts representing the issued shares was approved by the Swedish Financial Supervisory Authority and made public on 23 November, 2016. The Swedish depository receipts were admitted to trading on Nasdaq Stockholm on 25 November 2016.

Vostok is an investment company with a special focus on online marketplaces and businesses with strong network effects. As of 30 September 2016, the net asset value of the group was USD 632.44 million. The Swedish depository receipts of Vostok are listed on Nasdaq Stockholm, Mid Cap segment.

Vinge’s team primarily consisted of Jesper Schönbeck, David Andersson, Frida Bäckegren, Joel Wahlberg and Sara Osman.

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025